GENE ONLINE|News &
Opinion
Blog

China
Sanofi Invests in Innovent to Gain Stronger Foothold in China
2022-08-05
Everest, Calliditas Win First Approval for Rare Kidney Disease Drug in Europe
2022-07-18
Zhiyi Biotech Finishes Series B Funding With $45 Million For Live Biotherapeutics
2022-07-11
Brii Biosciences Begins Marketing COVID-19 Antibody Cocktail Therapy in China
2022-07-07
WuXi Biologics Adds Microbial Fermentation to CDMO Offering in Hangzhou
2022-07-05
Innovent, Lilly’s PD-1 Inhibitor Approved to Treat Esophageal Cancer in China
2022-06-21
Shenzhen Joincare Plots $300 Million IPO On Swiss Exchange
2022-06-20
Organon Licenses Biosimilars From Shanghai’s Henlius For $103 Million
2022-06-14
Everest Medicines Secures Breast Cancer Drug Approval in China
2022-06-13
Everest and Gilead Announce Positive Phase 3 Results of Breast Cancer Drug
2022-06-06
China’s Hengrui Buds Off New Biotech With 11 Therapeutic Programs
2022-05-19
BeiGene Granted NMPA Approval to Treat World’s Most Prevalent Esophageal Cancer
2022-04-20
Backed by RTW, LENZ Therapeutics Inks $110 Vision Loss Pact with China’s JIXING
2022-04-14
Shanghai’s Hasten Seals $322 Million Acquisition of Takeda Drugs
2022-04-06
Kintor Pharma’s Proxalutamide Demonstrated Reduction in Hospitalization/Mortality for Patients with Mild to Moderate COVID-19 in Phase III MRCT Study
2022-04-05
1 2 3 6
LATEST
A New Sequencer on the Horizon – Illumina Genomics Forum Days Two and Three Highlights
2022-09-30
Novo Nordisk Places $700 Million Bet on Ventus’ NLRP3 Inhibitor Program
2022-09-30
Amylyx’s ALS Drug Nabs FDA Nod After Rare Regulatory Reversal
2022-09-29
Illumina Reveals NovaSeq™ X Series at the Illumina Genomics Forum
2022-09-29
Illumina Genomics Forum Kicks Off With A Conversation With President Barack Obama
2022-09-29
First Patient in New Zealand Dosed with Illuccix® – Telix's Prostate Cancer Imaging Agent
2022-09-29
Samsung Biologics introduces new development platforms S-DUAL™ and DEVELOPICK™ at BPI Boston 2022
2022-09-29
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!